News
Sepsis multiplies in-hospital mortality risk in COPD
October 21, 2021
Among nearly 7 million hospitalizations in which the primary diagnosis was COPD, nearly 65,000 (0.93%) patients experienced sepsis as a complication.
News
Comorbidities larger factor than race in COVID ICU deaths?
October 21, 2021
Racial/ethnic disparities in COVID-19 mortality rates may be related more to comorbidities than to demographics, suggest authors of a new study.
News
Mortality in 2nd wave higher with ECMO for COVID-ARDS
October 19, 2021
“More research is required to develop stricter inclusion/exclusion criteria and to improve pre-ECMO management in order to improve outcomes.”
News
Biomarkers may indicate severity of COVID in children
October 15, 2021
"A model of six miRNAs was able to discriminate between severe and nonsevere infections with high sensitivity and accuracy in a preliminary analysis."
News
No short-term death risk in elderly after COVID-19 vaccines
October 13, 2021
Early reports of deaths shortly after mRNA-based vaccination of very frail elderly patients in Norway prompted a nationwide safety study.
News
Omega-3s tame inflammation in elderly COVID-19 patients
October 13, 2021
Those who received an intravenous infusion had significant decreases from baseline to end of treatment in the neutrophil-to-lymphocyte ratio.
News
Case reports underscore risk of cerebral edema, AFCE in children with COVID-19
October 7, 2021
Neurologists urge colleagues to watch for similar cases in children.
News
Antibody cocktail reduces chance of developing COVID
October 4, 2021
“This is the first long-acting combination of monoclonal antibodies that represents a potential new option to augment COVID-19 prevention.”
News
Age, C-reactive protein predict COVID-19 death in diabetes
September 29, 2021
“This means we can easily identify patients early on in their hospital stay who will likely require more aggressive interventions to try and improve survival.”
News
Remdesivir sharply cuts COVID hospitalization risk, Gilead says
September 23, 2021
An RCT evaluated the efficacy and safety of a 3-day course of intravenous remdesivir in an analysis of 562 nonhospitalized patients at high risk for disease progression.